Method of treating lewis Y-expressing tumors

US8323650B2 · kind B2 · utility

Assignees

• MERIDIAN BIOPHARMACEUTICALS GMBH · AT
• GREENOVATION BIOTECH GMBH · DE

Inventors

• Manfred Schuster · Schrick, AT
• Gottfried Himmler · Groß-Enzersdorf, AT
• Guenter Waxenecker · Mank, AT
• Geert Mudde · Purkersdorf, AT
• Manuela Loidl · Stockerau, AT
• Gerda Redl · Groß-Enzersdorf, AT
• Hans Loibner · Wien, AT

Key dates

• Filing date: May 24, 2010
• Grant date: Dec 4, 2012
• Expiry date: Jun 17, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/734
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.